

International Partners

INTERNATIONAL PARTNERS:
Institute scientists collaborate closely with major international and UK cancer organisations. The Institute's numerous partners include:

Dana-Farber Cancer Institute Boston, USA	M D Anderson Cancer Center Houston, USA
Deutsches Krebsforschungszentrum Heidelberg, Germany	McGill University Montreal, Canada
Fox Chase Cancer Center Philadelphia, USA	Mayo Clinic Rochester, USA
Het Nederlands Kanker Instituut Amsterdam, Netherlands	Mount Sinai Hospital Toronto, Canada
Institut Gustave-Roussy Paris, France	Memorial Sloan-Kettering Cancer Institute New York, USA
Istituto Europeo di Oncologia Milan, Italy	Weizmann Institute of Science Israel



LEUKAEMIA RESEARCH:
 Leukaemia Research provides a large programme grant to fund research carried out in the Section of Haemato-Oncology at The Institute.

THE BOB CHAMPION CANCER TRUST



THE BOB CHAMPION CANCER TRUST:
 The Institute is home to the UK's first dedicated male cancer research centre, funded in partnership with the Bob Champion Cancer Trust which provided £1m of the £3m raised to build the centre.



THE UNIVERSITY OF LONDON:
 As a College of the University of London, The Institute has direct authority to run its academic affairs to the very highest standards. Most importantly, The Institute is able to appoint its own professors, readers and PhD student supervisors.

THE NATIONAL CANCER RESEARCH INSTITUTE (NCRI):
 The Institute is currently in receipt of a grant of £3.2m over 5 years from the NCRI as one of only two NCRI Prostate Cancer Collaborative centres of research excellence. The NCRI is co-funded by the MRC, the Department of Health and Cancer Research UK.



THE MEDICAL RESEARCH COUNCIL (MRC):
 The MRC is one of the UK's largest research councils, funded by the UK taxpayer and independent in its choice of which research to support. The MRC is a significant funder of The Institute's work.




DEPARTMENT OF HEALTH:
 The Department of Health provides long-term core funding for The Institute's Cancer Screening Evaluation Unit and also finances certain epidemiological projects concerned with screening for various types of cancer.



THE WELLCOME TRUST SANGER INSTITUTE:
 Funded by the Wellcome Trust, the Sanger Institute is home to the Cancer Genome Project, initiated by Professor Mike Stratton and Dr Richard Wooster from The Institute.



THE WELLCOME TRUST:
 The Wellcome Trust supports the Cancer Genome Project at the Sanger Institute. The Trust also funds some of our basic molecular biology and genetic research and contributed just under £8m towards the construction of the Brookes Lawley Building.



CANCER RESEARCH UK:
 Cancer Research UK contributes almost a third of the Institute's total income and is its largest research funder. The Institute is home to two major Cancer Research UK Centres, for Cell and Molecular Biology and for Cancer Therapeutics.



BREAKTHROUGH BREAST CANCER:
 The Institute, in partnership with Breakthrough Breast Cancer, is home to the UK's first dedicated breast cancer research centre, 'The Breakthrough Toby Robins Breast Cancer Research Centre'.

THE ROYAL MARSDEN NHS FOUNDATION TRUST:
 The Institute has very close academic and research links with the Royal Marsden, with many staff holding joint or Honorary appointments in both institutions. This unique partnership forms Europe's largest Comprehensive Cancer Centre, employing scientists, clinicians and nurses.



THE HIGHER EDUCATION FUNDING COUNCIL FOR ENGLAND (HEFCE):
 As an educational institution, The Institute is entitled to apply for and receives funding from HEFCE. About a fifth of The Institute's total recurrent income is provided by HEFCE.

